India has the same yes or never admit failure embedded in

New Post Public Reply Private Reply Replies (0) Message Board
biotech7 AlwaysSum1ElsesFault #9211
361
India has the same yes or never admit failure embedded in their culture also. 99% of the time that is a positive attribute. From what I am reading and hearing antibodies from blood draws are in fact one of the methods of testing being considered. I am surprised that home testing kits are under consideration by the FDA, or I should say I was surprised.

We are headed towards a complete martial law as we are already in a soft one by many States. If this continues I doubt the majority of people will have any money to buy kits.

Getting one million dollars is peanuts, and as of today, the Company claims they only have received $500,000.00. Some of the claims made by the Company are ridiculous. Roche, for example, could only commit to delivering 400.000 testing kits despite working on this for months, Roche has high volume manufacturing plants. Looking back at prior manufacturing capabilities regarding the Diabetic devices one would think the claims were exaggerated, although the demand never materialized for the diabetic strips.

It will be interesting to see if our government, or any government, approves funding grants to this small company because I am in the camp that larger established companies will reap those benefits. If the technology proves out and there is decent production I can see some type of partnership with a Big Pharma. I can also visualize a big pharma going to the Korean contractor and buying out plant capacity for the next few years whereby crippling this Company.

my red flag from the press release has nothing to do with where this test is validated, but the wording that this device is only a "concept" at this point puts it in a category of a new drug that has not undergone any trials. I don't investors understand that because of exactly what you have pointed out, exaggeration or grandstanding. One thing is for sure, test kits that deliver accurate readings are needed very badly.

Decision Diagnostics Corp (DECN) Stock Research Links

DECN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Elevate Your Gaming Experience with Betblast’s New Features

Updated Category News Views 188

Unveiling the New Betblast Features for Gamers In a digital age where online gambling is immensely popular, players are consistently on the lookout for platforms that provide more than just entertainment but also real, significant rewards. One name that has emerged as a favorite among players for offering exceptional wins and rapid payouts is Betblast. As discussions...

Continue Reading
Kinetic Business Introduces Tailored Internet Solutions for SMBs

Updated Category News Views 91

Kinetic Business Introduces an Innovative Internet Solution Kinetic Business is stepping into the spotlight with an exciting new product that caters specifically to the needs of small businesses. Their latest offering, known as Business Ready Internet, aims to revolutionize how small enterprises manage their connectivity, security, and overall operational efficiency....

Continue Reading
The Surge of Ship-to-Shore Cranes: Market Insights Ahead

Updated Category News Views 108

Ship-to-Shore Cranes Market Overview As we look towards the future of the Ship-to-Shore (STS) cranes market, predictions indicate a significant expansion, with market size anticipated to reach USD 4.06 billion by 2032. This growth represents a compound annual growth rate (CAGR) of 4.41% from 2025 to 2032. The increasing emphasis on technological advancements in port...

Continue Reading
Chicago Rivet & Machine Co. Announces Quarterly Dividend Update

Updated Category News Views 93

Chicago Rivet & Machine Co. Announces Dividend Decision Chicago Rivet & Machine Co. (NYSE American: CVR) has made an important announcement regarding its dividend for shareholders. The Board of Directors has declared a quarterly cash dividend of $0.03 per share. This will be paid out to all shareholders who are recorded as of December 5 of the current fiscal year. While...

Continue Reading
Insights on the AstraZeneca PLC Class Action and Investor Rights

Updated Category News Views 140

Understanding the AstraZeneca PLC Class Action A class action lawsuit has been initiated on behalf of stockholders who purchased shares of AstraZeneca PLC (NASDAQ: AZN) between specific dates. Robbins LLP is actively reminding these investors of the critical lead plaintiff deadline. This class action highlights important allegations surrounding AstraZeneca and offers...

Continue Reading